ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

Core Insights - ImmunityBio reported a quarterly loss of $0.1 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.2 per share a year ago [1] - The company achieved revenues of $26.43 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 0.10%, and significantly up from $1.05 million year-over-year [2] - ImmunityBio shares have declined approximately 5.9% year-to-date, contrasting with the S&P 500's gain of 7.6% [3] Earnings Outlook - The earnings outlook for ImmunityBio is mixed, with the current consensus EPS estimate at -$0.10 on revenues of $27.17 million for the upcoming quarter, and -$0.45 on revenues of $96.77 million for the current fiscal year [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which ImmunityBio belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact ImmunityBio's stock performance [5]